You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
山東新華製藥股份(00719.HK)與中國藥科大學簽訂聯合研究合作協議
格隆匯 03-26 16:37

格隆匯 3 月 26日丨山東新華製藥股份(00719.HK)發佈關於與中國藥科大學簽訂聯合研究合作協議的公吿,2021年3月24日,山東新華製藥股份有限公司與中國藥科大學簽訂了“重大創新藥物和高端製劑聯合研究開發合作協議”。

公吿表示,公司與中國藥科大學本次項目合作是一次戰略合作。中國藥科大學在該領域的研究水平處於國內領先地位,在創新藥、高端製劑、改良型新藥等方面具有優勢,為公司提供製劑技術創新的關鍵理論、人才培養及技術服務;協助公司開展“中國藥科大學--新華製藥創新藥物及高端製劑聯合研究中心”及“新華製藥-中國藥科大學重大公共安全及應急用藥研發創新中心”建設,在創新藥立項、法規政策諮詢等方面提供技術指導。雙方在院士工作站、博士後工作站、研究生聯合培養、實訓實踐基地的建設上,建立長效合作機制,形成學術與人才互動。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account